



PRESS RELEASE
February 2, 2003
Uppsala, Sweden

Q-MED launches a new product for the treatment of fine superficial lines.

Q-Med has obtained approval in Europe for sales of the esthetics product RESTYLANE Touch.

RESTYLANE Touch is used for the treatment of fine superficial lines and is a further development of the previous product RESTYLANE Fine Lines. The substance, and thereby the product's injection properties, have been improved. RESTYLANE Touch achieves smoother lifting of fine superficial lines around the eyes and mouth in a natural and safe way.

"RESTYLANE Touch enables us to strengthen our position as market leader regarding both small and larger, deeper wrinkles," says Anna Tenstam Lundvall, Vice President of the Esthetics Business Unit.

Like Q-Med's other esthetics products, RESTYLANE Touch is based on the company's patented NASHA technology.

Queries should be addressed to:

Mikael Svensson, Marketing Director, Esthetics, tel: +46 (0)73-387 15 16
Fredrik Hallstan, Manager Investor Relations and Corporate Communications,
tel: +46 (0)70-974 90 15.

Visit: www.restylane.com

Note: Q-Med AB operates under the name of Q-Med Scandinavia, Inc. in the USA.

Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces and markets medical implants. All products are based on the company's patented technology for the production of NASHA - Non-Animal Stabilized Hyaluronic Acid. The products RESTYLANE, RESTYLANE Touch and RESTYLANE Perlane are used for the filling out of lips and facial wrinkles and today account for the majority of sales. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the knee joint, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Since July Q-Med today has 450 employees, with approximately 300 at the company's production facility and head office in Uppsala. The Q-Med share was first listed on the O-list of the Stockholm Stock Exchange in December 1999.